THE PEPTIDE INTERNET · WITH RECEIPTS✳PRIMARY RECORDS OVER PRESS RELEASES✳UNKNOWN IS A REAL ANSWER✳NO PRODUCTS · NO PROTOCOLS · NO VENDORS✳EDUCATIONAL JOURNALISM · NOT MEDICAL ADVICE✳THE PEPTIDE INTERNET · WITH RECEIPTS✳
The Peptide Current Issue 01
Updated July 25, 2026
The Current · Issue 01

BPC-157 was not “legalized.”

In April 2026, FDA removed BPC-157 and eleven other substances from Category 2 of its interim compounding categories. That changed one regulatory barrier. It did not approve BPC-157, add it to the 503A Bulks List, or authorize every product sold under the name.

Published May 11, 2026Post-meeting update July 25, 2026Independent source review complete
The TL;DR

“Removed from Category 2” and “legalized” are not synonyms. FDA staff later recommended against placing BPC-157 on the 503A Bulks List for the nominated ulcerative-colitis use. On July 23, the advisory committee then recommended inclusion of both BPC-157 free base and BPC-157 acetate, with separate 8–6–1 votes. The committee advice is non-binding, and FDA’s final determination is still pending. None of those steps verifies the identity or quality of an online product.

Claim lens

You heard: “BPC-157 got legalized.”

The sourced version: One interim restriction changed, and the advisory committee later recommended inclusion of both BPC-157 forms. FDA approval, final list placement, and product authentication did not follow.

Confidence: Established for the dated regulatory sequence; unknown for any unidentified product.

What changed

  • Category 2 removal took effect April 22, 2026.
  • FDA published staff briefing material for the July 23–24 committee meeting.
  • The committee separately recommended inclusion of BPC-157 free base and BPC-157 acetate by 8 Yes, 6 No, and 1 Abstain for each form.
  • PepCurrent continues to separate staff review, committee advice, and final FDA action in the FDA Tracker.

What did not change

  • BPC-157 is not an FDA-approved drug.
  • Category 2 removal did not itself place BPC-157 on the 503A Bulks List.
  • The advisory votes did not themselves create final list placement.
  • A regulatory event did not create new human efficacy evidence or verify products sold online.

What we could not verify

PepCurrent found no controlled human tendon-repair trial supporting the broad online “Wolverine peptide” claim.

Three receipts

  1. Federal Register meeting notice
  2. FDA voting questions
  3. PepCurrent BPC-157 FDA status file
PepCurrent sells no peptides, recommends no vendors, and publishes no protocols. Educational journalism, not medical or legal advice.
Open the current BPC-157 status →Read the verification log →